NasdaqGS - Nasdaq Real Time Price USD
Cogent Biosciences, Inc. (COGT)
6.90
+0.10
+(1.47%)
At close: June 9 at 4:00:01 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 185.59k | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| PINNOW COLE Officer | Purchase at price 7.60 per share. | Direct | 332,412 | Jan 14, 2025 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Director | -- | Indirect | -- | Jun 10, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 7.50 per share. | Indirect | 8,749,995 | Feb 16, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | Indirect | 9,600,000 | Jun 9, 2023 |
| SACHS JESSICA M.D. Officer | Stock Award(Grant) at price 7.39 per share. | Direct | 4,600 | Jun 30, 2022 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.25 per share. | Indirect | 9,900,000 | Jun 16, 2022 |
| SACHS JESSICA M.D. Officer | Stock Award(Grant) at price 8.58 per share. | Direct | 5,783 | Dec 31, 2021 |
| GREEN JOHN L Chief Financial Officer | Sale at price 8.86 per share. | Direct | 157,823 | Apr 26, 2021 |
| GREEN JOHN L Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 25, 2021 |
| GREEN JOHN L Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Dec 1, 2020 |
| VHCP MANAGEMENT L L C Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.30 - 2.62 per share. | Indirect | 1,137,120 | Aug 18, 2020 |
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.30 - 2.62 per share. | Indirect | 1,137,120 | Aug 18, 2020 |
| GREEN JOHN L Chief Financial Officer | -- | Direct | -- | Jul 6, 2020 |
| CAMPANA DARIO M.D. PH.D. Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.33 - 0.46 per share. | Indirect | 788,383 | May 12, 2020 |
| ETTENBERG SETH PH.D. Officer | Sale at price 4.12 per share. | Direct | 47,334 | Mar 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Mar 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Sale at price 4.12 per share. | Direct | 47,334 | Mar 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Mar 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Sale at price 4.25 per share. | Direct | 48,853 | Feb 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Feb 25, 2019 |
| ETTENBERG SETH PH.D. Officer | Sale at price 4.05 per share. | Direct | 46,487 | Dec 26, 2018 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Dec 26, 2018 |
| ETTENBERG SETH PH.D. Officer | Sale at price 7.00 per share. | Direct | 80,444 | Nov 26, 2018 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Nov 26, 2018 |
| ETTENBERG SETH PH.D. Officer | Sale at price 8.46 per share. | Direct | 97,201 | Oct 25, 2018 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Oct 25, 2018 |
| ETTENBERG SETH PH.D. Officer | Sale at price 12.47 per share. | Direct | 143,181 | Sep 25, 2018 |
| ETTENBERG SETH PH.D. Officer | Conversion of Exercise of derivative security at price 0.18 per share. | Direct | 2,067 | Sep 25, 2018 |
| RATCLIFFE LIAM T Director | Purchase at price 12.00 per share. | Indirect | 6,600,000 | Apr 3, 2018 |
| RATCLIFFE LIAM T Director | -- | Indirect | -- | Apr 3, 2018 |
| ATLAS VENTURE FUND LP Director | Purchase at price 12.00 per share. | Indirect | 1,128,624 | Apr 3, 2018 |
| ATLAS VENTURE FUND LP Director | -- | Indirect | -- | Apr 3, 2018 |
| ATLAS VENTURE FUND III LP Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | Indirect | 1,128,624 | Apr 3, 2018 |
| ATLAS VENTURE FUND III LP Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Apr 3, 2018 |
| FMR LLC Unknown | Purchase at price 12.00 per share. | Indirect | 1,128,624 | Apr 3, 2018 |
| FMR LLC Unknown | -- | Indirect | -- | Apr 3, 2018 |
| FIL, LTD. Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Apr 3, 2018 |
| FIL LTD. Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Apr 3, 2018 |
Related Tickers
KURA Kura Oncology, Inc.
6.73
0.00%
CNTA Centessa Pharmaceuticals plc
11.94
+0.17%
DAWN Day One Biopharmaceuticals, Inc.
7.08
-1.53%
ZBIO Zenas BioPharma, Inc.
11.92
+7.19%
PTGX Protagonist Therapeutics, Inc.
55.68
+2.39%
EWTX Edgewise Therapeutics, Inc.
15.26
+0.13%
VRDN Viridian Therapeutics, Inc.
14.86
+1.23%
AMLX Amylyx Pharmaceuticals, Inc.
5.44
+2.06%
TYRA Tyra Biosciences, Inc.
10.26
-2.75%
NRIX Nurix Therapeutics, Inc.
12.54
-1.88%